0

Toxicological Assessment of Gadoversetamide Injection (OptiMARK), a New Contrast-Enhancement Agent for Use in Magnetic Resonance Imaging

J H Wible Jr, C M Troup, M R Hynes, K P Galen, J R MacDonald, S J Barco, J K Wojdyla, M P Periasamy, M D Adams

Invest Radiol. 2001 Jul;36(7):401-12.

PMID: 11496095

Abstract:

Rationale and objectives:
A series of preclinical tests were undertaken during the developmental process to determine the safety profile of gadoversetamide injection (OptiMARK).
Methods:
Acute intravenous, acute intracisternal, and repeated-dose toxicities; cardiovascular effects; and genetic and reproductive toxicology characteristics were assessed in several animal species.
Results:
Gadoversetamide injection demonstrated an acute intravenous median lethal dose of 25 to 28 mmol/kg and a maximum nonlethal dose of 14 mmol/kg in mice. In the dog, acute administration of gadoversetamide injection showed a no observable effect level at 3 mmol/kg. Dosed daily for 4 weeks, gadoversetamide injection (0.1 mmol x kg(-1) x d(-1)) caused no serious irreversible changes in any organs in rats and dogs. At a dose of 0.1 mmol/kg, gadoversetamide injection caused no significant (P < 0.05) changes in cardiovascular function in anesthetized dogs. Gadoversetamide injection showed no mutagenic activity. Fertility, reproductive performance, and postnatal fetal development were not affected at doses up to 0.5 mmol x kg(-1) x d(-1) in the rat. No teratogenicity was observed at doses up to 4.2 mmol x kg(-1) x d(-1) in the rat and up to 1.6 mmol x kg(-1) x d(-1) in the rabbit.
Conclusions:
Data from our toxicological assessment demonstrate the safety of gadoversetamide injection in a number of animal species at doses exceeding the intended human clinical dose.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
AP131069915 Gadoversetamide Gadoversetamide 131069-91-5 Price
qrcode